TRV GP II’s Sage Therapeutics SAGE Stock Holding History

TRV GP II’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-37,362	Closed	-$3.58M	–	4
2018 Q4	$3.58M	Hold	37,362	–	–	3.56%	4
2018 Q3	$5.28M	Hold	37,362	–	–	3.1%	4
2018 Q2	$5.85M	Hold	37,362	–	–	3.32%	4
2018 Q1	$6.02M	Sell	37,362 -510,554	-93%	-$86.7M	1.13%	5
2017 Q4	$90.2M	Buy	+547,916	New	+$53.1M	16.25%	4

Other funds holding SAGE

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

TRV GP II's SAGE Position: Q1 2019 in Review

TRV GP II sold out of Sage Therapeutics (SAGE) in Q1 2019, closing a stake of 37,362 shares — an estimated $3.58M sold.

TRV GP II first reported a position in SAGE in Q4 2017 and held it in 5 quarters. The position peaked at $90.2M in Q4 2017. 267 funds tracked by Wall St. Rank hold SAGE as of Q1 2019.

TRV GP II reported no remaining Sage Therapeutics position as of Q1 2019 after selling out during the quarter.
TRV GP II sold 37,362 Sage Therapeutics shares in Q1 2019, an estimated $3.58M.
TRV GP II first reported a position in Sage Therapeutics in Q4 2017 and held it in 5 quarters.
TRV GP II's Sage Therapeutics position peaked at $90.2M in Q4 2017.
267 funds tracked by Wall St. Rank held Sage Therapeutics as of Q1 2019.

Based on TRV GP II's 13F filing for Q1 2019, filed 3 May 2019.